The Court dismissed the case of misuse of market power and exclusive dealing conduct around its atorvastatin products.

In 2014, companies misrepresented the origins of their products, the types of products used and the methods of farming.

Importing Ozempic without a valid prescription would constitute a ‘prohibited import' under the Customs Act 1901.

It is already legal to recreationally use and personally possess cannabis in the Australian Capital Territory.

This decision may allow innovators to block the launch of certain generics, even without a claim of patent infringement.

Guidance when dealing with the Department of Agriculture regarding breaches of regulations

This was an appeal against an earlier order to cancel a Pharmacist's registration, because of professional misconduct.

NCAT was not relevantly satisfied that Mr Fryar was a fit and proper person to be re-registered as a pharmacist.

A panel of three experts would conduct an independent review of the TGA regulation of medicines and medical devices.

Lodging an application for listing on the Pharmaceutical Benefits Scheme does not constitute exploitation of a patent.

These changes reflect a new approach to health policy, with more collaboration between Government and key stakeholders.

Objections to registration of pharmaceutical trade marks based on the inclusion of an INN stem remain a concern.

The Federal Court provided further guidance regarding how infringement of a Swiss-style patent claim is established.

This is a brief wrap-up of recent decisions relating to pharma trade marks from the EU, the United States and Australia.

This article looks at key aspects of the Vioxx decision and the implications for life sciences companies and insurers.

With rising COVID-19 infections, TGA issued new guidance on the public advertising and supply of rapid antigen tests.

Primary producers must ensure reasonable measures, records and systems are in place to try to avoid food contamination.

Primary producers should take all reasonable measures and have suitable systems to ensure contamination does not occur.

This should provide guidance for patent holders on how to legitimately compete, on the expiry of their exclusive rights.

The long-running representative action brought on behalf of consumers of the arthritis drug, Vioxx, has been settled.